======= SRSF2 ======= == Gene Information == * **Official Symbol**: SRSF2 * **Official Name**: serine and arginine rich splicing factor 2 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=6427|6427]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q01130|Q01130]] * **Interactions**: [[https://thebiogrid.org/search.php?search=SRSF2&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20SRSF2|Open PubMed]] * **OMIM**: [[https://omim.org/entry/600813|Open OMIM]] == Function Summary == * **Entrez Summary**: The protein encoded by this gene is a member of the serine/arginine (SR)-rich family of pre-mRNA splicing factors, which constitute part of the spliceosome. Each of these factors contains an RNA recognition motif (RRM) for binding RNA and an RS domain for binding other proteins. The RS domain is rich in serine and arginine residues and facilitates interaction between different SR splicing factors. In addition to being critical for mRNA splicing, the SR proteins have also been shown to be involved in mRNA export from the nucleus and in translation. Two transcript variants encoding the same protein and one non-coding transcript variant have been found for this gene. In addition, a pseudogene of this gene has been found on chromosome 11. [provided by RefSeq, Sep 2010]. * **UniProt Summary**: Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre- mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment. {ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:21157427}. |RRM 1| |interchromatin granule| |response to vitamin E| |pre-mRNA binding| |mRNA cis splicing, via spliceosome| |protein kinase C binding| |regulation of alternative mRNA splicing, via spliceosome| |mRNA 3-end processing| |response to vitamin| |spliceosomal complex| |regulation of mRNA splicing, via spliceosome| |PML body| |mRNA export from nucleus| |mRNA-containing ribonucleoprotein complex export from nucleus| |ribonucleoprotein complex export from nucleus| |ribonucleoprotein complex localization| |RNA export from nucleus| |RNA 3-end processing| |regulation of RNA splicing| |regulation of mRNA processing| |protein export from nucleus| |mRNA transport| |nuclear export| |nucleic acid transport| |RNA transport| |establishment of RNA localization| |response to nutrient| |RNA localization| |nucleobase-containing compound transport| |transcription corepressor activity| |protein-containing complex localization| |nucleocytoplasmic transport| |nuclear transport| |RNA splicing, via transesterification reactions with bulged adenosine as nucleophile| |mRNA splicing, via spliceosome| |RNA splicing, via transesterification reactions| |regulation of mRNA metabolic process| |RNA splicing| |nuclear speck| |mRNA processing| |response to nutrient levels| |response to extracellular stimulus| |mitotic cell cycle| |mRNA metabolic process| |RNA processing| |response to organic cyclic compound| |intracellular protein transport| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |negative regulation of RNA metabolic process| |cell cycle| |RNA binding| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |protein transport| |negative regulation of cellular biosynthetic process| |intracellular transport| |peptide transport| |negative regulation of biosynthetic process| |response to oxygen-containing compound| |amide transport| |cellular protein localization| |cellular macromolecule localization| |establishment of protein localization| |RNA metabolic process| |establishment of localization in cell| |nitrogen compound transport| |gene expression| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp126|GSK461364A 0.1μM R03 exp126]]|-2.11| |[[:results:exp346|CoCl2 18μM R07 exp346]]|-1.91| |[[:results:exp334|All-trans-Retinoic-Acid 40μM R07 exp334]]|-1.9| |[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-1.9| |[[:results:exp300|VE-822 0.04μM R06 exp300]]|-1.82| |[[:results:exp439|QNZ 0.01μM R08 exp439]]|-1.79| |[[:results:exp426|FBS-Wisent 0.1 R07 exp426]]|-1.77| |[[:results:exp94|Nocodazole 0.1μM R03 exp94]]|-1.72| |[[:results:exp159|Docetaxel 0.001 to 0.002μM on day4 R04 exp159]]|-1.71| |[[:results:exp460|BML-284 0.09μM R08 exp460]]|1.7| |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|1.74| |[[:results:exp11|CCCP 1μM R00 exp11]]|2.07| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 725/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|1/1| |909776.0|1/1| |bile duct|28/28| |blood|28/28| |bone|25/25| |breast|33/33| |central nervous system|56/56| |cervix|4/4| |colorectal|17/17| |esophagus|13/13| |fibroblast|1/1| |gastric|15/15| |kidney|21/21| |liver|20/20| |lung|75/75| |lymphocyte|14/14| |ovary|26/26| |pancreas|24/24| |peripheral nervous system|16/16| |plasma cell|15/15| |prostate|1/1| |skin|24/24| |soft tissue|7/7| |thyroid|2/2| |upper aerodigestive|21/22| |urinary tract|29/29| |uterus|5/5| == Essentiality in NALM6 == * **Essentiality Rank**: 16 * **Expression level (log2 read counts)**: 9.24 {{:chemogenomics:nalm6 dist.png?nolink |}}